LFCR Stock Forecast & Price Target

Lifecore Biomedical is currently in the execution phase of its turnaround effort, with new business wins and expense management demonstrating significant progress. The company's pipeline is also growing both in quantity and quality, with an estimated annualized revenue value of over $100 million in late-stage and site transfer projects. The recent addition of a CDMO industry veteran as Chief of Staff suggests further opportunities for business transformation and optimization. While the company's leverage may be a concern, its management has provided guidance indicating a strong long-term financial outlook. In recent news, Lifecore has signed two new agreements, highlighting the success of its commercial strategy and forecasting meaningful commercial revenue in 2028. These wins are in addition to three previous site transfer wins, demonstrating momentum in the company's efforts to become a top manufacturing partner. Our target price for Lifecore is based on EV/EBITDA, with potential risks including failure to meet revenue or earnings estimates.

Lifecore Biomedical is experiencing some recent commercial success with four new site transfer agreements signed since October 2025. While these agreements are not expected to generate significant revenue until 2028, they offer promising signs for the company's commercial strategy of increasing capacity utilization through low-risk opportunities. This, however, may not be enough to outweigh the company's overall negative outlook, as revenue from these agreements will likely contribute minimally to the company's financials in the near future.